Programs & Services

#TeamVaccines - International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

#TeamVaccines spotlights the positive impact of vaccines on the world, explains the benefits of vaccines at every age and stage of life, and champions their future potential to save even more lives.

50 Years of Progress - International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

50 Years of Progress is an initiative that engages with the personal stories of individuals whose lives have been transformed over 50 years of building a better world through health innovations, overcoming challenges, making scientific advances, and partnering for progress.

Alternatives to the Traditional Mental Health System - Mindfreedom International

Anatomy Fund - The Foundation for Excellence in Mental Health Care

Supporting professional study groups by underwriting the distribution of Robert Whitaker’s groundbreaking book, Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America.

Augmented Psychotherapy Training (APT) - MIND Foundation

The Augmented Psychotherapy Training (APT) is a two-year program that provides you with the knowledge and skills you need to practice psychedelic-augmented psychotherapy and psychedelic integration therapy in a legal, safe, and evidence-based framework.

BDZ Digital Health - Reconnexion

Reconnexion collaborated with Federation University to develop an online self-guided benzodiazepine tapering program called BDZ Digital Health. Early evidence shows BDZ Digital Health is just as effective at supporting individuals to safely cease their benzodiazepine or z-drug as face-to-face interventions (like Reconnexion’s benzo counselling program) making it a great alternative for individuals who cannot access our program or who want to do a self-guided taper.

Benzodiazepine Counsellors - Reconnexion

Recconnexion's experienced counsellors work with you and your GP to design a gradual reduction that suits your needs. Your counsellor will meet regularly with you to work on managing any withdrawal symptoms you may experience, as well as supporting you to overcome issues that emerge as you reduce your benzos such as anxiety, insomnia and depression.  Before you begin counselling, you will be stepped through the intake process over the phone. Your first counselling appointment(s) will focus on assessment to ensure you remain very much in control of the process. Most clients then have regular weekly or fortnightly appointments. The length of treatment required varies from person to person – for some people it is relatively quick and straightforward but for others it may take many months.

Benzodiazepine Guided Support Group - Reconnexion

A Benzodiazepine Guided Support Group is a facilitated group for people recovering from benzodiazepine withdrawal. Whilst receiving support, you also give help and hope to others through sharing the challenges and the successes you have experienced in withdrawal.

Benzodiazepine secondary consultations - Reconnexion

Reconnexxion's experienced benzodiazepine counsellors can provide free secondary consultations by phone to health professionals working with a patient or client who has issues with benzodiazepine use or withdrawal. 

Beyond Experience - MIND Foundation

Beyond Experience is a course that provides a comprehensive skill set for working with the whole spectrum of psychedelic experiences, both personally and when supporting others. The course’s main goal is to engage in a deep integration process and help you remember and express your psychedelic experiences. 

Biologics and Other Specialised Medicines - NPS Medicine Wise

Biologics and other specialised medicines have made a significant improvement in the management of chronic diseases like inflammatory arthritis, inflammatory bowel disease and plaque psoriasis. ​On this page you will find evidence-based resources to support consumers and health professionals to make safe and wise decisions for using these medicines.

Choosing Wisely Australia - NPS Medicine Wise

Choosing Wisely Australia is a national conversation about reducing unnecessary tests, treatments and procedures

Cope, Take Care of Yourself - Inner Compass Initiative

The Withdrawal Project’s Cope, Take Care of Yourself, and Heal section is a comprehensive, curated resource that holds the gathered experiences, learnings, tips, strategies and tools that we at TWP and many others have found helpful along our withdrawal journeys.The Withdrawal Project’s Cope, Take Care of Yourself, and Heal is a collectively developed, shared community resource of the psychiatric drug withdrawal community.

• Withdrawal Symptoms A to Z: an A to Z list of psychiatric drug withdrawal symptoms is comprised of many years of accumulated anecdotal reports from the layperson withdrawal community. 
• Coping Techniques A to Z: a curated list of tips, techniques, modalities, practices, exercises, and activities that people have reported to be effective for coping both with specific psychiatric drug withdrawal symptoms and with the whole withdrawal experience more broadly.
• Reclaim Your Health: information and resources aimed at helping you take back the innate power to heal and reclaim your brain and body through non-clinical, non-medical, “common sense” methods that laypeople have found beneficial along the withdrawal journey.

Directory of Alternative Providers - Mindfreedom International

The Directory of Alternative Providers is a searchable online database for mental and emotional support. 

Drugs and Treatment - Mind

Mind provides information on a number of drug and treatment options. These include:

• Antidepressants
• Antidepressants A-Z
• Antipsychotics
• Antipsychotics A-Z
• Arts & Creative Therapies
• Cognitive Behavioural Therapy
• Complementary & Alternative Therapies
• Dialectical Behaviour Therapy (DBT)
• Nature & Mental Health
• Electroconvulsive Therapy
• Lithium & Other Mood Stabilisers
• Psychiatric Medication
• Coming Off Psychiatric Drugs
• Minfulness
• Neurosurgery for mental disorder (NMD)
• Sleeping Pills & Minor Tranquilisers
• Sleeping pills & minor tranquillisers A-Z
• St John's wort - Hypericum perforatum
• Talking Therapies & Counselling

Footsteps - MIND Foundation

Footsteps is an online integrated journey in which you learn to integrate psychedelic experiences online. Over the course of six weeks, you will reconnect deeply with one of your psychedelic experiences in order to identify and embody the insights you have gained in sustainable ways. 

Global Health Progress - International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Global Health Progress explores how the innovative pharmaceutical industry is collaborating with global health actors to achieve the Sustainable Development Goals (SDGs).

Inner Compass Exchange - Inner Compass Initiative

Inner Compass Exchange provides space for community members to support one another, organize virtual and in-person groups and events, and engage in conversation about the immediate and longer-term questions, concerns, and challenges that arise from taking or coming off psychiatric drugs, receiving psychiatric diagnoses, or otherwise engaging with the mental health industry.

Inner Compass Learn - Inner Compass Initiative

Inner Compass Initiative has developed the mini-booklets, articles and Q&As in this section because descriptions of psychiatric diagnoses and treatments that are provided by most major medical and mental health websites are usually brief, vague and more “promotional” than factual. There are many reasons that some of these websites might knowingly or unwittingly promote misleading ideas about diagnoses and treatments – reasons that are explained in detail in some of our essays. Conversely, we believe that when seeking information to help make serious, potentially life-changing decisions about the well-being of your own (or a friend or loved one’s) body, brain, mind and spirit, you deserve a fairer opportunity to understand and evaluate the facts and potential risks and benefits. We believe that everyone deserves to be empowered to make truly informed choices.

KarXT - Karuna Pharmaceuticals

KarXT is Karuna's lead product candidate that selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase 2 studies in schizophrenia and Alzheimer’s. Karuna assessed the potential of over 7,000 possible combinations of muscarinic receptor agonists and antagonists to find an optimized combination that could preferentially stimulate muscarinic receptors in the CNS to improve the symptoms of psychosis, while avoiding stimulation of muscarinic receptors in the peripheral tissues and the associated side effects. As a result of our research, we identified xanomeline and trospium as the most promising pairing for development in the form of KarXT (Karuna-xanomeline-trospium). Trospium is a potent and effective muscarinic receptor antagonist that does not measurably cross the blood-brain barrier, confining its effects to peripheral tissues, and it currently marketed for the treatment of overactive bladder in the U.S. and other territories worldwide. Karuna co-founder and chief operating officer, Andrew Miller, Ph.D., was responsible for identifying the initial hypothesis and driving the execution of the completed Phase I studies supporting the combination of xanomeline and trospium.

Despite xanomeline’s promising therapeutic benefit in treating psychosis and related behavioral symptoms in patients with schizophrenia and AD, its potential has been limited by cholinergic side effects, which are believed to result from the stimulation of muscarinic receptors in peripheral tissues. Karuna believes that the above data, as well as our Phase 1 and 2 clinical trials with KarXT demonstrating robust efficacy and significant reductions in the adverse events associated with xanomeline, support the further development of KarXT in multiple neuropsychiatric disorders, including schizophrenia and dementia-related psychosis.

Medication Optimisation - National Empowerment Centre (NEC)

Medication optimization is a term used by peers, professionals, family members and advocates calling for the adoption sound medication prescription protocols based in shared decision making, informed consent, and the principle of ‘do no harm.’

• Foundation for Excellence in Mental Health Care: a foundation focusing on identifying, developing, and sharing knowledge with the public about mental health care that best helps people recover and live well in society. They promote improvements in mental health care by sponsoring research and the development of programs designed to help people thrive–physically, mentally, socially and spiritually. C
• When Government Propaganda Masquerades as Science (Robert Whitaker)
• Rxisk.org: is the drug safety website that provides a database to research and report side effects.

Medicine Finder - NPS Medicine Wise

A database created by NPS Medicinewsie wehre you can learn more about many types of medicines that are prescribed or recommended for treatment.

MedicineInsight - NPS Medicine Wise

MedicineInsight is a quality improvement program developed and managed by NPS MedicineWise with funding from the Australian Government Department of Health and Aged Care.

Medicines Assistance Tool (MAT) - Pharmaceutical Research and Manufacturers of America (PhRMA)

PhRMA’s Medicine Assistance Tool (MAT) is a search engine designed to help patients, caregivers and health care providers learn more about the resources available through the various biopharmaceutical industry programs. MAT is not its own patient assistance program, but rather a search engine for many of the patient assistance resources that the biopharmaceutical industry offers.

MIND Integration Facilitator Training - MIND Foundation

The MIND Integration Facilitator Training is training for those who have participated in BEYOND EXPERIENCE (BE) and FOOTSTEPS and want to bring the integrative approach to the psychedelic experience into the world. 

MIND Philosophy Series - MIND Foundation

The MIND Philosophy series intends to provide an accessible overview of philosophical issues that arise in relation to psychedelics, psychedelic use, and psychedelic research.

Molecules - MIND Foundation

The Molecules Program offers a unique transdisciplinary and evidence-based approach to knowledge about psychoactive substances. Being the first program of its kind, we have developed this platform for academics, health practitioners, and the general public. You will be able to acquire and integrate knowledge and practices from different disciplines and professions.

Novel MOA - Karuna Pharmaceuticals

Current antipsychotic treatments rely on the same primary mechanism of action (MOA) as they did when the first antipsychotic was discovered in the 1950s: inhibiting D2 dopamine receptors. Current antipsychotics are often used by physicians to address a wide range of neuropsychiatric disorders in addition to schizophrenia, including bipolar disorder and psychotic depression, as well as psychosis and agitation in elderly patients with dementia, but are associated with modest efficacy and significant side effects.

Muscarinic receptor agonists emerged in the 1990s as a promising innovative approach for treating psychosis and cognitive impairment. Muscarinic receptors are g-protein linked receptors (GPCRs) that bind the neurotransmitter acetylcholine. There are five distinct muscarinic receptors, M1-M5, found in the brain as well as various peripheral tissues.

The link between muscarinic receptor stimulation in the CNS, particularly stimulation of M1 and M4 receptors, and the reduction of psychotic symptoms and cognitive impairment, has been well studied and is supported by data from preclinical studies and randomized, double-blind, placebo-controlled clinical trials with xanomeline published in peer reviewed journals. However, the successful development of a therapeutic agent targeting muscarinic receptors has been limited by undesirable side effects that are believed to arise primarily as a result of stimulation of muscarinic receptors in peripheral tissues. We believe a therapeutic agent that can preferentially target and stimulate muscarinic receptors in the CNS, but not in peripheral tissues, has the potential to treat psychosis in schizophrenia and AD, including the associated agitation in patients with AD. We also believe the preferential stimulation of M1 and M4 muscarinic receptors in the CNS may address the negative symptoms of schizophrenia, such as apathy, reduced social drive and loss of motivation, as well as cognitive deficits in working memory and attention, all of which currently lack any approved treatments. This approach has the potential to produce a differentiated therapy relative to current D2 dopamine receptor-based antipsychotic drugs and to beneficially impact the lives of millions of patients with schizophrenia and other psychotic and cognitive disorders.

Pipeline - Karuna Pharmaceuticals

Karuna's pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.

Pipeline - Pharnext

Pharnext has an advanced clinical-stage pipeline. Two first-in-class products in clinical development

• PXT3003: is a novel synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice daily for harcot-Marie-Tooth Disease type 1A (CMT1A). 
• PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice daily for alzheimer's disease

PLEOTHERAPYâ„¢ - Pharnext

PLEOTHERAPY™ is Pharnext's proprietary technology platform, systemizes the identification and development of new drug combinations for any disease that currently lack effective treatments. These new treatment candidates – called PLEODRUG™ – are expected to feature high levels of efficacy and safety as they target several disease pathways simultaneously and are formulated with optimal doses of their components.

This new visionary concept in drug development is based on network pharmacology. From all biological data associated with a disease, notably genomic big data, and the use of Artificial Intelligence tools, Pharnext builds the disease molecular network which is a set of interconnected potential therapeutic targets. From this network, Pharnext screens, in silico and experimentally, generic compounds approved for unrelated indications and/or NCEs to develop novel drug combinations that hit multiple highly relevant disease targets. We then create new formulations of the newly identified treatment candidate (each component with a new specific dose and ratio), called PLEODRUG™, that are tested in humans through a full clinical development plan. In addition to a potentially excellent efficacy and safety profile, PLEODRUG™ are expected  to offer other potential advantages: fast, affordable development (up to pre-Phase 2 POC in ~2.5 years) and robust intellectual property (Composition of Matters and Method of Use patents).

Pharnext’s PLEOTHERAPY™ approach in drug development is universally applicable to any disease or compound, regardless of development stage or lifecycle status. It has been validated by worldwide-renowned scientists and institutions, including Nobel Prize laureates, but also through R&D collaborations with renowned companies Galapagos and Tasly Pharmaceuticals.

Psychiatric Drug Industry - Mindfreedom International

Psychiatric Drugs - Mindfreedom International

A variety of information about psychiatric prescribed medications, including neuroleptic brain damage, deaths and psychiatric drugs, and resources about quitting psychiatric drugs.

QI Hub - NPS Medicine Wise

QI Hub provides practical information, tools and resources for health professionals and staff in general practice to help improve the quality of health care and safety for patients.

The COVID-19 Innovation Timeline - International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

The COVID-19 Innovation Timeline is an initiative that discovers the innovative pharmaceutical industry’s response to the COVID-19 pandemic to inform how we can better prepare for the next public health crisis.

The EPIsoDE Study - MIND Foundation

The EPIsoDE Study is being conducted by the Central Institute of Mental Health (CIMH) in Mannheim, Germany (Principal Investigator: Prof. Dr. med. Gerhard Gründer). A second study center has been established at Charité Universitätsmedizin Berlin. The study is funded by the German Federal Ministry of Education and Research (BMBF). The MIND Foundation is an official study partner providing expertise, personnel, and additional funding.

The acronym “EPIsoDE” (Efficacy and safety of Psilocybin In treatment-reSistant majOr DEpression) summarizes the aim of the study: To investigate whether psilocybin administered under supportive conditions in a controlled, randomized, double-blind design is a safe and effective treatment for depression patients whose symptoms cannot be adequately reduced with antidepressants. Over the course of the study, 144 patients will be treated in Mannheim and Berlin. The rationale and study design are explained in detail in a recent article published in the scientific journal Neuroscience Applied.

The Harm Reduction Guide to Coming off Psychiatric Drugs - Mind Freedom International

The Harm Reduction Guide to Coming Off Psychiatric Drugs is an illustrated guide with the best information available coming off psychiatric medication. Based in more than 10 years work in the peer support movement, this Guide is used internationally by individuals, families, professionals, and organizations, and is available a growing number of translations. Includes info on:

• Mood stabilizers
• Anti-psychotics
• Anti-depressants
• Anti-anxiety drugs
• Risks 
• Benefits
• Wellness tools
• Psychiatric drug withdrawal
• Information for people staying on their medications
• Detailed Resource section, and much more.

A ‘harm reduction’ approach means not being pro- or anti- medication, but supporting people where they are at to make their own decisions, balancing the risks and benefits involved. Written by Will Hall, with a 55-member health professional Advisory Board providing research assistance and more than 50 collaborators involved in developing and editing. The guide has photographs and art throughout, and a beautiful original cover painting by Jacks McNamara. Now in a revised and expanded Second Edition.

The Roland R. Griffiths, Ph.D., Professorship Fund - American College of Neuropsychopharmacology (ACNP)

The Roland R. Griffiths, Ph.D., Professorship Fund aims for the endowment is to ensure that rigorous research on psychedelics, spirituality, and well-being. This research will extend Roland R. Griffiths’ pioneering studies on psychedelics into programmatic lines of research. 

The Withdrawal Project (TWP) - Inner Compass Initiative

The Withdrawal Project (TWP) is an information resource designed to help people empower themselves to make more meaningfully informed choices — aligned with their personal desires and needs — regarding taking, reducing, and coming off psychiatric drugs. TWP's website includes a free, comprehensive, self-directed Companion Guide to Psychiatric Drug Withdrawal aimed at helping people learn and make decisions about the most risk-minimizing ways to prepare for tapering off and more responsibly taper off antidepressants, benzodiazepines, stimulants, antipsychotics, mood stabilizers, Z-drugs and other psychiatric drugs, along with coping techniques for dealing with common withdrawal symptoms

Together Against Flu - International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

#TogetherAgainstFlu campaign continuously raises awareness of the importance of flu vaccinations for healthcare workers, older adults, and patients living with chronic conditions.

TWP Connect - Inner Compass Initiative

TWP Connect is a one-on-one networking tool hosted on ICI’s Withdrawal Project website allows registered members who are thinking about, are in the process of, or have past experiences of reducing or coming off psychiatric drugs to find and connect with one another. TWP Connect facilitates mutual support, the sharing of helpful resources and tips, in-person meetings, and hope and inspiration between members. 

uniMIND - MIND Foundation

uniMIND is a global network of academic journal clubs, open to academics of all levels and disciplines with the focus on mind, brain, and psychedelic research. Local groups operate mostly autonomously through regular meetings in which research literature, academic talks, documentaries, or projects are discussed. Besides, there are monthly central web-sessions with invited authors and the yearly uniMIND Symposium. 

Value Assessment Initiative - PhRMA Foundation

The PhRMA Foundation’s Value Assessment Initiative promotes the development of advanced value-assessment so decision makers have better tools to assess high- and low-value care in the U.S. health system. The initiative funds new research and innovative efforts to assess the value of medicines and health care services, improve patient outcomes and reduce inefficiency.

Voters For Cures - Pharmaceutical Research and Manufacturers of America (PhRMA)

Voters for cures is a branch of PhRMA to take action on important policy issues affecting all Americans. It operates within the unique policy and regulatory framework in the United States supports innovation and access to medicines.